Form 4: Select Medical Holdings Executive Chairman Robert Ortenzio Sells 50,000 Shares

Robert Ortenzio, Executive Chairman of Select Medical Holdings, sold 50,000 shares of common stock at an average price of $29.90, according to a recent SEC filing.

Summary

• Robert A. Ortenzio, the Executive Chairman of Select Medical Holdings Corporation, sold 50,000 shares of common stock on April 8, 2024.
• The sale was executed at a weighted average price of $29.90 per share, with individual transaction prices ranging from $29.72 to $30.20.
• The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on December 9, 2022.
• Following the transaction, Ortenzio directly owns 6,689,668 shares of Select Medical Holdings common stock.
• Ortenzio also indirectly owns shares through various trusts, including the Robert A. Ortenzio Descendants Trust (1,279,000 shares), the Rocco A. Ortenzio Separate Exempt Descendants Trust (3,804,805 shares), and several 2014 trusts for his children (280,415 shares each).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports an insider sale under a pre-existing 10b5-1 plan. It doesn't inherently indicate positive or negative sentiment towards the company's future.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors for signals about a company's prospects. A 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Comparison to Industry Standards

• Comparing Ortenzio's transactions to other healthcare executives' trading activity would provide context.
• For example, if other executives in similar companies like Universal Health Services or HCA Healthcare are also selling shares, it could indicate broader industry trends or individual company-specific factors.
• Analyzing the size and frequency of these transactions relative to their overall holdings is also important.
• A large sale by an executive with a small stake might be more concerning than a small sale by an executive with a significant stake.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment if investors interpret it as a lack of confidence by the Executive Chairman, although the 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates